In this episode, I talked with Chris Lowe, CEO of Nusano, where he discusses his career journey in the medical technology field, particularly focusing on the production of medical radioisotopes. He shares insights on leadership, the importance of building a talented team, and the societal responsibilities of his company. Chris also highlights common mistakes in drug development and reflects on a case study from his past. Our conversation emphasizes the significance of patient-centric approaches in the industry.

Here's what you're in:

• The highest and lowest career points of Chris’ career.
• Why medical radioisotopes production is so important and how Nusano is approaching this.
• Exploring mistakes that companies are still making today.

Timestamps:

04:51 Proudest Moment of Chris in his Career and Leadership Philosophy

07:41 Nusano: Innovations in Medical Radioisotope Production

13:55 Building a Talented Team at Nusano

17:57 Company Culture and Societal Responsibility

19:48 Common Mistakes Companies Are Still Making Today

22:40 Case Study: The Francis Trial

30:24 Final Thoughts on Patient-Centric Drug Development

About Chris

Chris Lowe is the CEO of Nusano, a privately-held medical technology company that specializes in the production of medical radioisotopes used for diagnosing and treating diseases such as cancer. Chris has led 5 IPOs as a C-level executive, all focused on supporting therapeutic development, while efficiently building and scaling operations.

Prior to this, he spent 3 years with Cortexyme as COO and CFO. He has over 15 years of C-Suite experience in various private and public life sciences, medical technology, and technology companies.

Connect with Chris

LinkedIn: https://www.linkedin.com/in/chrislowe7/

Company Website: https://nusano.com/

About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with me:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

Opinions and comments expressed by the guest do not represent the company and are fully their own.